Literature DB >> 27891379

Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.

Harpreet Singh1, Gagandeep Sukhija2, Vikram Tanwar2, Sameer Arora2, Jaikrit Bhutani3.   

Abstract

Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Skin ucleration, vasculitis, lichenoid drug rash and Subacute Cutaneous Lupus Erythematosus (SCLE) have been rarely reported with its use. A rare case of Leflunomide induced SCLE is being reported in a female patient with rheumatoid arthritis. The clinical features, histopathological and immunological characteristics were consistent with drug induced SCLE. Withdrawal of Leflunomide along with short course of topical steroids resulted in resolution of symptoms suggesting the drug to be the culprit. As this drug comes into widespread use, it remains to be seen whether more cases of DI-SCLE will occur/be reported. Fortunately, such a condition till times appears rare and is reversible once the drug is discontinued thus avoiding over evaluation and over treatment if the triggering drug is recognized.

Entities:  

Keywords:  DI-SCLE; Immunomodulatory drug; Rheumatoid arthritis

Year:  2016        PMID: 27891379      PMCID: PMC5121717          DOI: 10.7860/JCDR/2016/14508.8667

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  Subacute cutaneous lupus erythematosus associated with leflunomide.

Authors:  O A Kerr; C S Murray; M J Tidman
Journal:  Clin Exp Dermatol       Date:  2004-05       Impact factor: 3.470

Review 2.  A systematic review of drug-induced subacute cutaneous lupus erythematosus.

Authors:  G C Lowe; G Lowe; C L Henderson; R H Grau; C B Hansen; R D Sontheimer
Journal:  Br J Dermatol       Date:  2011-02-17       Impact factor: 9.302

3.  Leflunomide-induced subacute cutaneous lupus erythematosus.

Authors:  V Goëb; J M Berthelot; P Joly; O Mejjad; J de Quatrebarbes; C Reynaud-Hautin; O Vittecoq; X Le Loët
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580

4.  Subacute cutaneous lupus erythematosus precipitated by leflunomide.

Authors:  S K Chan; B L Hazleman; N P Burrows
Journal:  Clin Exp Dermatol       Date:  2005-11       Impact factor: 3.470

5.  Lupus erythematosus with leflunomide: induction or reactivation?

Authors:  D Gensburger; M Kawashima; H Marotte; J Kanitakis; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

6.  Subacute cutaneous lupus erythematosus associated with leflunomide.

Authors:  Anthony R Elias; Christine C Tam; Kathleen M David-Bajar
Journal:  Cutis       Date:  2005-09

7.  Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil.

Authors:  Petra Cetkovská; Karel Pizinger
Journal:  Int J Dermatol       Date:  2006-03       Impact factor: 2.736

8.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

9.  Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy.

Authors:  B R Reed; J C Huff; S K Jones; P W Orton; L A Lee; D A Norris
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

  9 in total
  1 in total

Review 1.  Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Authors:  Ye He; Amr H Sawalha
Journal:  Curr Opin Rheumatol       Date:  2018-09       Impact factor: 5.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.